Officer Marino Garcia Files to Sell $13.6M in Dianthus Therapeutics Stock
DNTH has more than doubled off its 52-week low of $18.08.
Summary
Dianthus Therapeutics officer Marino Garcia filed to sell 126,000 shares worth ~$13.6 million, adding to a recent pattern of insider selling near the stock's 52-week high.
Key Events · Ownership and Investor Activity · DNTH
-
Officer Files to Sell $13.6M
Marino Garcia, an officer, filed a Form 144 to sell 126,000 shares worth approximately $13.6 million, acquired via option exercise on the same day.
-
Part of Broader Insider Selling
This filing follows $7.99 million in net insider sales over the past 90 days by three insiders, indicating a distribution trend.
-
Sale Near 52-Week High
The proposed sale comes with the stock trading near its 52-week high of $114.55, potentially reflecting insiders locking in gains after positive Phase 3 data.
-
No Prior Sales by This Filer
The filer reported no securities sold in the past three months, making this a new selling intent.
Analysis · DNTH · Life Sciences
Officer Marino Garcia filed a Form 144 to sell 126,000 shares worth approximately $13.6 million, acquired via option exercise on the same day. The sale represents about 0.22% of outstanding shares and comes amid a pattern of insider selling over the past 90 days, with net sales of nearly $8 million by three insiders. While the stock is trading near its 52-week high following positive Phase 3 data, this filing adds to the distribution signal from insiders, though the sale is not yet executed and may be part of a pre-existing plan.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1457 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DNTH was trading at $108.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $18.08 to $114.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.